EP. 1: When to Start Systemic Treatment in Newly Diagnosed RCC
EP. 2: Goals of Therapy in Advanced RCC
EP. 3: Determining Initial Therapeutic Approach in Advanced RCC
EP. 4: Choosing Among TKIs in Advanced RCC
EP. 5: RCC First-Line Toxicity Considerations
EP. 6: Assessing Treatment Response with RCC First-Line Therapies
EP. 7: Advanced RCC Sequencing Challenges
EP. 8: Patient Selection and Checkpoint Inhibition in RCC
EP. 9: The Rationale for Cabozantinib in Advanced RCC
EP. 10: Options in the Third Line Setting for RCC
EP. 11: The Role of Lenvatinib in Advanced RCC
EP. 12: Second and Third-Line Decisions in RCC
EP. 13: Long-Term RCC Data with Nivolumab
EP. 14: Novel Approaches in Advanced RCC
EP. 15: A Changing Landscape in RCC
EP. 16: A Look to the Future in RCC
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
